IMPACT-HTA multicriteria value framework
A structured method to assess health technologies by combining multiple factors like effectiveness, cost, patient impact, and broader societal values into an overall value judgment.
At a glance
Use when
Assessing innovative or high-cost therapies; evaluating treatments for rare diseases; when traditional cost-effectiveness analysis is insufficient; need for inclusive, transparent decision processes.
Avoid when
Rapid assessment is required with limited data; when only head-to-head clinical trial data is available without broader context; in systems with rigid, purely economic decision rules.
Inputs
Scores and weights for predefined criteria across clinical, economic, patient, and societal domains; input from stakeholders including clinicians, patients, and payers.
Outputs
A composite value score for a health technology; a transparent rationale for the assessment; comparative analysis across technologies.
How it works
A multicriteria decision analysis (MCDA) framework developed within the IMPACT-HTA project that enables systematic, transparent weighting and scoring of diverse criteria across clinical, economic, patient-reported, and societal domains to inform HTA decisions.
- Project
- IMPACT HTA
- Funding
- Horizon 2020
- Project status
- Completed 2021
- HTA domains
- Aspects Beyond HTA
- Categories
- Appraisal
- Technology
- Medicines
- Assumptions
- Relevant criteria can be defined and measured; stakeholders can provide meaningful weights; value is multidimensional and not captured by cost-effectiveness alone; transparency improves legitimacy of decisions.
- Strengths
- Comprehensive and transparent; incorporates diverse perspectives including patients; allows comparison across different types of technologies; supports structured decision-making in complex cases.
- Limitations
- Requires significant stakeholder input and resources; weighting can be subjective; implementation in real-world HTA processes may be challenging; not all criteria are easily quantifiable.
- Also known as
- IMPACT-HTA MCDA, IMPACT-HTA framework
Questions this answers
- › How can we compare new health technologies when they differ in effectiveness, cost, and impact on patients' lives?
- › What factors beyond just clinical benefit and cost should be considered in health technology assessment?
- › How can patient and societal values be formally included in decisions about which treatments to fund?
- › How can decision makers be more transparent about how they weigh different aspects of a technology's value?
- › Can we create a fairer system for assessing treatments for rare diseases or high unmet need?
- › How do we combine expert and patient input when evaluating a new therapy?
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.